Pharming Group NV (PHGN)

Currency in EUR
0.962
+0.123(+14.59%)
Delayed Data·
PHGN Scorecard
Full Analysis
High shareholder yield
PHGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.9320.962
52 wk Range
0.6481.066
Key Statistics
Bid/Ask
0.94 / 0.977
Prev. Close
0.84
Open
0.932
Day's Range
0.932-0.962
52 wk Range
0.648-1.066
Volume
4.1K
Average Volume (3m)
4.23K
1-Year Change
5.99%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Pharming Group NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Pharming Group NV Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Employees
404
Market
Germany

Compare PHGN to Peers and Sector

Metrics to compare
PHGN
Peers
Sector
Relationship
P/E Ratio
−47.1x−3.4x−0.5x
PEG Ratio
1.53−0.090.00
Price/Book
3.1x2.7x2.6x
Price / LTM Sales
2.1x6.2x3.3x
Upside (Analyst Target)
-63.2%42.4%
Fair Value Upside
Unlock18.0%7.2%Unlock

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
79.09M / --
EPS Revisions
Last 90 days

PHGN Income Statement

People Also Watch

613.10
ASML
-2.29%
427.50
ASMI
-4.47%
27.52
MT
-2.58%
119.10
BESI
-2.70%
6.284
AEGN
+0.54%

FAQ

What Stock Exchange Does Pharming Group NV Trade On?

Pharming Group NV is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Pharming Group NV?

The stock symbol for Pharming Group NV is "PHGN."

What Is the Pharming Group NV Market Cap?

As of today, Pharming Group NV market cap is 660.48M.

What Is Pharming Group NV's Earnings Per Share (TTM)?

The Pharming Group NV EPS (TTM) is -0.02.

From a Technical Analysis Perspective, Is PHGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Pharming Group NV Stock Split?

Pharming Group NV has split 1 times.

How Many Employees Does Pharming Group NV Have?

Pharming Group NV has 404 employees.

What is the current trading status of Pharming Group NV (PHGN)?

As of 31 Jul 2025, Pharming Group NV (PHGN) is trading at a price of 0.96, with a previous close of 0.84. The stock has fluctuated within a day range of 0.93 to 0.96, while its 52-week range spans from 0.65 to 1.07.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.